Isis Pharmaceuticals Reports Interim Results from ISIS-SMN Rx Phase 2 Study in Infants with Spinal Muscular Atrophy

[PR Newswire] – CARLSBAD, Calif., Feb. 21, 2014 /PRNewswire/ — Isis Pharmaceuticals, Inc. (ISIS) today provided an update on its ongoing open label, multiple dose Phase 2 study of ISIS-SMNRx in infants with spinal muscular atrophy (SMA). To date, all fo more

View todays social media effects on ISIS

View the latest stocks trending across Twitter. Click to view dashboard

See who Isis is hiring next, click here to view